Page last updated: 2024-09-04

lonafarnib and etoposide

lonafarnib has been researched along with etoposide in 2 studies

Compound Research Comparison

Studies (lonafarnib)	Trials (lonafarnib)	Recent Studies (post-2010) (lonafarnib)	Studies (etoposide)	Trials (etoposide)	Recent Studies (post-2010) (etoposide)
224	34	90	18,306	3,693	4,900

Protein Interaction Comparison

Protein	Taxonomy	etoposide (IC50)
nuclear receptor coactivator 1 isoform 1 [Homo sapiens]	Homo sapiens (human)	1.153
nuclear receptor coactivator 3 isoform a	Homo sapiens (human)	1.4284
Polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus (rabbit)	3.187
Caspase-3	Homo sapiens (human)	1
DNA topoisomerase 2-beta	Homo sapiens (human)	0.4299
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	4.18

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bishop, WR; Izbicka, E; Lawrence, RA; Petit, T; Von Hoff, DD; Weitman, S	1
Bishop, WR; Nakajima, A; Ohyashiki, K; Sumi, M; Tauchi, T	1

Other Studies

2 other study(ies) available for lonafarnib and etoposide

Article	Year
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:4 Topics: Alkyl and Aryl Transferases; Cell Survival; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Humans; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Piperidines; Pyridines; Sensitivity and Specificity; Tumor Cells, Cultured; Tumor Stem Cell Assay	1999
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Molecular cancer therapeutics, 2003, Volume: 2, Issue:3 Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured	2003

Article

Year

Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.

Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:4

Topics: Alkyl and Aryl Transferases; Cell Survival; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Humans; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Piperidines; Pyridines; Sensitivity and Specificity; Tumor Cells, Cultured; Tumor Stem Cell Assay

1999

Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.

Molecular cancer therapeutics, 2003, Volume: 2, Issue:3

Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myeloid, Acute; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection; Treatment Outcome; Tumor Cells, Cultured

2003